Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
0(0%)
Results Posted
75%(3 trials)
Terminated
1(20%)

Phase Distribution

Ph phase_1
3
60%
Ph phase_3
2
40%

Phase Distribution

3

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
3(60.0%)
Phase 3Large-scale testing
2(40.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(4)
Terminated(1)

Detailed Status

Completed4
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
80.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (60.0%)
Phase 32 (40.0%)

Trials by Status

completed480%
terminated120%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_1

Study to Investigate the Mass Balance, Metabolism, and Excretion of [14C]-PF-07304814 in Healthy Participants

NCT05050682
terminatedphase_3

PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

NCT05780541
completedphase_3

ACTIV-3: Therapeutics for Inpatients With COVID-19

NCT04501978
completedphase_1

First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending And Multiple Ascending Doses of PF-07304814 In Hospitalized Participants With COVID-19.

NCT04535167
completedphase_1

Single Ascending Dose Study of Intravenous Infusion of PF 07304814 in Healthy Adult Participants

NCT04627532

Clinical Trials (5)

Showing 5 of 5 trials
NCT05050682Phase 1

Study to Investigate the Mass Balance, Metabolism, and Excretion of [14C]-PF-07304814 in Healthy Participants

Completed
NCT05780541Phase 3

PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

Terminated
NCT04501978Phase 3

ACTIV-3: Therapeutics for Inpatients With COVID-19

Completed
NCT04535167Phase 1

First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending And Multiple Ascending Doses of PF-07304814 In Hospitalized Participants With COVID-19.

Completed
NCT04627532Phase 1

Single Ascending Dose Study of Intravenous Infusion of PF 07304814 in Healthy Adult Participants

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5